Pfizer Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $129.84B
  • PE 16
  • Debt $62.11B
  • Cash $1.48B
  • EV $190.47B
  • FCF $11.22B

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$7.88B
EBIT$7.39B
ROE9%
ROA4%
FCF$11.22B
Equity$90.64B
Growth Stability10%
PE16.47
PEG-1.48
PB1.43
P/FCF11.57
P/S2.08
Price/Cash0.01
Debt/Equity0.69
Debt/FCF5.54
Net Margins22%
Gross Margins72%
Op. Margins12%
Earnings CAGR1%
Sales Growth YoY-8%
Sales Growth QoQ-23%
Sales CAGR5%
FCF CAGR-4%
Equity CAGR5%
Earnings Stability0
Earnings Growth YoY-5%
Earnings Growth QoQ624%
Earnings CAGR 5Y-11%
Sales CAGR 5Y5%
FCF CAGR 5Y-19%
Equity CAGR 5Y9%
Earnings CAGR 3Y-21%
Sales CAGR 3Y-21%
FCF CAGR 3Y-40%
Equity CAGR 3Y-2%
Market Cap$129.84B
Revenue$62.46B
Dividend Yield7%
Payout Ratio121%
Assets$208.03B
Total Debt$62.11B
Cash$1.48B
Shares Outstanding5.68B
EV190.47B
Earnings Score6%
Moat Score73%
Safety Score54%
Final Score44%
Working Capital9.41B
Current Ratio1.26
Gross Profit$45.15B
Shares Growth 3y0%
Equity Growth QoQ2%
Equity Growth YoY-2%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

SEC Filings

Direct access to Pfizer Inc (PFE) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 30
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 29
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Oct 01
    • 10-Q Jul 02
    • 10-Q Apr 02

Sector Comparison

How does Pfizer Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Pfizer Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%
Stability 0%
loading chart...

Pfizer Inc Discounted Cash Flow

Fully customizable DCF calculator online for Pfizer Inc.

= $88B
012345678910TV
fcf$11B$11B$10B$10B$9.6B$9.3B$8.9B$8.6B$8.3B$8B$7.7B$77B
DCF$9.8B$8.6B$7.5B$6.6B$5.8B$5B$4.4B$3.9B$3.4B$3B$30B
Value$88B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins14%14%41%21%31%23%27%31%4%13%22%
ROA-6%7%7%11%5%13%18%0%4%4%
ROE-12%30%17%26%15%28%33%2%9%9%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-2.9933.035.013.281.271.38156.545.54
Debt over Equity0.60.70.610.650.820.630.50.370.810.730.69
Growth Stability---94%100%59%100%100%10%43%10%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-8%-1%2%-4%-20%95%23%-42%9%5%
Earnings YoY growth-4%195%-48%46%-41%129%43%-93%279%-11%
Equity YoY growth--8%20%-11%-0%0%22%24%-7%-1%9%
FCF YoY growth-7%3%-5%-24%17%149%-14%-82%105%-19%